Jason B. Fleming

31.5k total citations · 3 hit papers
329 papers, 18.9k citations indexed

About

Jason B. Fleming is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jason B. Fleming has authored 329 papers receiving a total of 18.9k indexed citations (citations by other indexed papers that have themselves been cited), including 237 papers in Oncology, 103 papers in Surgery and 83 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jason B. Fleming's work include Pancreatic and Hepatic Oncology Research (195 papers), Cancer Genomics and Diagnostics (51 papers) and Neuroendocrine Tumor Research Advances (50 papers). Jason B. Fleming is often cited by papers focused on Pancreatic and Hepatic Oncology Research (195 papers), Cancer Genomics and Diagnostics (51 papers) and Neuroendocrine Tumor Research Advances (50 papers). Jason B. Fleming collaborates with scholars based in United States, Japan and China. Jason B. Fleming's co-authors include Douglas B. Evans, Matthew H. G. Katz, Jean‐Nicolas Vauthey, Jeffrey E. Lee, Eddie K. Abdalla, Asif Rashid, Huamin Wang, James C. Yao, James L. Abbruzzese and Robert A. Wolff and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Jason B. Fleming

318 papers receiving 18.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

2008 3.3k citations Jason B. Fleming, Douglas B. Evans et al. profile →
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway

2013 1.5k citations Haoqiang Ying, Ya’an Kang et al. profile →
Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease

2008 592 citations Matthew H. G. Katz, Douglas B. Evans et al. profile →

Peers

Countries citing papers authored by Jason B. Fleming

Since Specialization

Citations

This map shows the geographic impact of Jason B. Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason B. Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason B. Fleming more than expected).

Fields of papers citing papers by Jason B. Fleming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason B. Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason B. Fleming. The network helps show where Jason B. Fleming may publish in the future.

Co-authorship network of co-authors of Jason B. Fleming

This figure shows the co-authorship network connecting the top 25 collaborators of Jason B. Fleming. A scholar is included among the top collaborators of Jason B. Fleming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason B. Fleming. Jason B. Fleming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition 2025 ·Cancer Research ·Gilbert Z. Murimwa, (unknown), Dina Alzhanova, (unknown), Jill M. Westcott, Francisca Beato, (unknown), (unknown), Francesca Rossi, (unknown), (unknown), (unknown), Jason E. Toombs, Jason B. Fleming, Aatur D. Singhi, (unknown), Huocong Huang, Rolf A. Brekken	2
2	346 Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal (CRC) and GI cancers 2023 ·SHILAP Revista de lepidopterología ·Matthew Beatty, (unknown), MacLean Hall, (unknown), (unknown), Larissa A. Pikor, (unknown), (unknown), Jamie K. Teer, Jason B. Fleming, Shari Pilon‐Thomas	0
3	Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis 2022 ·Cancers ·(unknown), Pilar Suz, Tea Reljic, (unknown), Ambuj Kumar, Benjamin D. Powers, Jonathan Strosberg, Jason W. Denbo, Jason B. Fleming, Daniel A. Anaya	13
4	A comparative Proteomics Analysis Identified Differentially Expressed Proteins in Pancreatic Cancer–Associated Stellate Cell Small Extracellular Vesicles 2022 ·Molecular & Cellular Proteomics ·Bhaswati Sarcar, Bin Fang, Victoria Izumi, Yury O. Núñez López, (unknown), Richard E. Pratley, Daniel Jeong, Jennifer B. Permuth, John M. Koomen, Jason B. Fleming, Paul A. Stewart	8
5	Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition 2021 ·Cancer Research ·Yan Liang, Bo Tu, Jun Yao, Jing Gong, Alessandro Carugo, Christopher A. Bristow, Qiuyun Wang, Cihui Zhu, Bingbing Dai, Ya’an Kang, Leng Han, Ningping Feng, (unknown), Jason B. Fleming, Timothy P. Heffernan, Wantong Yao, Haoqiang Ying	30
6	Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer 2021 ·Clinical Cancer Research ·Aslamuzzaman Kazi, Liwei Chen, Shengyan Xiang, (unknown), Hua Yang, Francisca Beato, Bin Fang, Terence M. Williams, Kazim Husain, Patrick W. Underwood, Jason B. Fleming, Mokenge P. Malafa, Eric A. Welsh, John M. Koomen, José G. Treviño, Saı̈d M. Sebti	25
7	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors 2019 ·Clinical Cancer Research ·Aslamuzzaman Kazi, Shengyan Xiang, Hua Yang, Liwei Chen, Perry Kennedy, Muhammad Ayaz, Steven Fletcher, Christopher T. Cummings, Harshani R. Lawrence, Francisca Beato, Ya’an Kang, Michael P. Kim, Andrea E. Delitto, Patrick W. Underwood, Jason B. Fleming, José G. Treviño, Andrew D. Hamilton, Saı̈d M. Sebti	53
8	Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer 2019 ·JCI Insight ·Meifang Yu, Nicholas D. Nguyen, Yanqing Huang, Daniel Lin, Tara N. Fujimoto, Jessica M. Molkentine, Amit Deorukhkar, Ya’an Kang, F. Anthony San Lucas, (unknown), Eugene J. Koay, Sonal Gupta, Haoqiang Ying, Albert C. Koong, Joseph M. Herman, Jason B. Fleming, Anirban Maitra, Cullen M. Taniguchi	129
9	SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy 2018 ·Clinical Cancer Research ·Feng Wang, Xiaojun Xia, Chunying Yang, (unknown), Junhua Mai, (unknown), Dickson Kirui, Ya’an Kang, Jason B. Fleming, Eugene J. Koay, Sankar Mitra, Mauro Ferrari, Haifa Shen	123
10	Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma 2017 ·Molecular Cancer Therapeutics ·Bingbing Dai, David Roife, Ya’an Kang, Joy Gumin, (unknown), Xinqun Li, Michael Pratt, Rolf A. Brekken, Juàn Fueyo, Frederick F. Lang, Jason B. Fleming	17
11	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma 2017 ·Molecular Cancer Therapeutics ·Kristina Y. Aguilera, Huocong Huang, Wenting Du, (unknown), Zhen Wang, Stefan Hinz, Tae Hyun Hwang, Huamin Wang, Jason B. Fleming, Diego H. Castrillón, Xiaomei Ren, Ke Ding, Rolf A. Brekken	88
12	IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma 2016 ·Cancer Research ·Song Gao, Yan Sun, (unknown), Limei Hu, Yuexin Liu, Corrine Ying Xuan Chua, Lynette M. Phillips, He Ren, Jason B. Fleming, Huamin Wang, Paul J. Chiao, Jihui Hao, Wei Zhang	88
13	Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors 2016 ·Clinical Cancer Research ·Ya’an Kang, David Roife, Yeon‐Ju Lee, (unknown), Rei Suzuki, Jianhua Ling, (unknown), Xinqun Li, Bingbing Dai, Michael Pratt, Mark J. Truty, Deyali Chatterjee, Huamin Wang, Ryan M. Thomas, Yu Wang, Eugene J. Koay, Paul J. Chiao, Matthew H. G. Katz, Jason B. Fleming	29
14	Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma 2016 ·Clinical Cancer Research ·David Roife, Bingbing Dai, Ya’an Kang, (unknown), Michael Pratt, Xinqun Li, Jason B. Fleming	46
15	IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation 2015 ·Clinical Cancer Research ·Zhuonan Zhuang, Huai‐Qiang Ju, Mitzi Aguilar, (unknown), Hao Li, Tomonori Iida, Harold Lee, (unknown), Haijun Zhou, Jianhua Ling, Zhongkui Li, Jie Fu, Min Wu, Min Li, Davide Melisi, Yoichiro Iwakura, Kesen Xu, Jason B. Fleming, Paul J. Chiao	95
16	Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery 2014 ·Clinical Cancer Research ·Xinqun Li, (unknown), Ya’an Kang, Xavier Chopin‐Laly, Ran Zhang, David Roife, Deyali Chatterjee, E. Lin, Ryan M. Thomas, Huamin Wang, Matthew H. G. Katz, Jason B. Fleming	69
17	K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways 2009 ·Molecular Cancer Research ·Yoichi Matsuo, Paul M. Campbell, Rolf A. Brekken, Bokyung Sung, Michel M. Ouellette, Jason B. Fleming, Bharat B. Aggarwal, Channing J. Der, Sushovan Guha	68
18	TrkBT1 Induces Liver Metastasis of Pancreatic Cancer Cells by Sequestering Rho GDP Dissociation Inhibitor and Promoting RhoA Activation 2009 ·Cancer Research ·Zhongkui Li, Zhe Chang, (unknown), Ya’an Kang, Qianghua Xia, Cihui Zhu, Jason B. Fleming, Douglas B. Evans, Paul J. Chiao	45
19	Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice 2008 ·Cancer Research ·Seán Dineen, Kristi D. Lynn, Shane E. Holloway, Andrew F. Miller, James P. Sullivan, David S. Shames, Adam W. Beck, Carlton C. Barnett, Jason B. Fleming, Rolf A. Brekken	161
20	LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis 2008 ·Molecular Cancer Therapeutics ·Davide Melisi, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese, Paul J. Chiao	262

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact